Evaluation Of Biotherapeutic Sequence Coverage Using Electron Activated Dissociation (EAD)

By Fang Wang, Zoe Zhang, Pavel Ryumin, Takashi Baba, Bill Lloyd, Jason Causon, and Kerstin Phol

Ensuring drug safety and efficacy is essential for biotherapeutics, which drives the need for in-depth characterization during their development. The data presented here demonstrate that novel electron activated dissociation (EAD) is highly comparable to traditionally used collision induced dissociation (CID) with regards to sequence coverage in a peptide mapping workflow. CID is considered the fold standard for MS/MS experiments, offering a fast dissociation mechanism, and highly reproducible results.

However, CID has known limitations. Here, a new fragmentation type based on EAD was evaluated and compared to CID, it provides better sensitivity, reproducibility, and acquisition speeds while maintaining comparable sequence coverage and fragment ion coverage.